tosatoxumab
Trade name: Salvecin
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03816956)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Alpha-hemolysinINHIBITOR
Alpha-hemolysin inhibitor
- Staphylococcus aureusImmunity, passive
Staphylococcus aureus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594526 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03816956 | Phase 3 | Mar 31, 2019 | Aridis Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aridis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1